These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 5693367)
41. [Effectiveness of oxyprogesterone-capronate in threatened abortion]. Pashchenko AG Vopr Okhr Materin Det; 1968 Apr; 13(4):59-63. PubMed ID: 5703209 [No Abstract] [Full Text] [Related]
42. Importance of hormone assays and high dose HCG, estrogen and 17-alpha-hydroxyprogesterone treatment in the prevention of threatened abortion due to endocrine causes. Cubesi G; Plancher G; Destro F Acta Eur Fertil; 1970 Sep; 2(3):355-8. PubMed ID: 5538329 [No Abstract] [Full Text] [Related]
44. An evaluation of the androgenic activity in threatened abortion. Krawczuk A; Szamatowicz M; Szamatowicz J Endokrinologie; 1973 May; 61(2):161-7. PubMed ID: 4796967 [No Abstract] [Full Text] [Related]
45. [Hydrolysis of urinary pregnanediol and pregnanetriol conjugates and its clinical significance]. Okamura Y; Tateyama H Horumon To Rinsho; 1968 Apr; 16(4):315-8. PubMed ID: 5692428 [No Abstract] [Full Text] [Related]
46. [Urinary excretion of estrogens, 5-beta-pregnane-3-alpha, 20-alpha diol, 5-beta-pregnane-3-alpha, 17-alpha, 20-alpha-triol and HCG in cases of normal and pathological pregnancy compared with plasma steroid and HCG levels]. Hamacher M; Nolden HW; Patt V; Leyendecker G; Nocke W Arch Gynakol; 1973 Sep; 214(1):208-11. PubMed ID: 4801429 [No Abstract] [Full Text] [Related]
47. [Relation between certain functional aspects and clinical symptomatology in the premenstrual syndrome (comparative clinical-biochemical study in 8 patients)]. Perini O; Cargnello U; Giordani G; Faelli U Friuli Med; 1968; 23(6):1027-58. PubMed ID: 5754150 [No Abstract] [Full Text] [Related]
48. Current status of estrogen assay in gynecology and obstetrics. I. Estrogen assays in gynecology and early pregnancy. Brown JB; Beischer NA Obstet Gynecol Surv; 1972 Apr; 27(4):205-35. PubMed ID: 4614140 [No Abstract] [Full Text] [Related]
49. [Behavior of the percentage ratio of urinary pregnanolone and urinary pregnanediol in some cases of grave fetal distress. Comparison with the estrogen excretion curve]. Campagnoli C; Capra A; Massobrio M; Garetto A Boll Soc Ital Biol Sper; 1970 Feb; 46(4):145-9. PubMed ID: 5516257 [No Abstract] [Full Text] [Related]
50. [Estradiol and pregnanldiol excretion in threatening miscarriages in late period of pregnancy depending on the cause of miscarriage]. Kosheleva NG; Savchenko ON Vopr Okhr Materin Det; 1977 Jul; 22(7):70-3. PubMed ID: 906385 [No Abstract] [Full Text] [Related]
51. Correlation between vaginal cytology and urinary hormone assays in pregnancy. MacRae DJ Acta Cytol; 1967; 11(1):45-50. PubMed ID: 4961816 [No Abstract] [Full Text] [Related]
52. [Use of central electroanalgesia for treating threatened abortions]. Bashmakova NV Vopr Okhr Materin Det; 1980 Feb; 25(2):54-6. PubMed ID: 7368646 [No Abstract] [Full Text] [Related]
53. Elevated urine estrogen and pregnanediol levels in daughters of breast cancer patients. Trichopoulos D; Brown JB; Garas J; Papaioannou A; MacMahon B J Natl Cancer Inst; 1981 Sep; 67(3):603-6. PubMed ID: 6944532 [TBL] [Abstract][Full Text] [Related]
54. [Urinary excretion of 17-ketosteroids, pregnanediol and pregnanetriol in essential arterial hypertension]. Lorè F; Manasse G Boll Soc Ital Cardiol; 1981; 26(4):339-43. PubMed ID: 7340867 [No Abstract] [Full Text] [Related]